Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $45.00 at Citigroup

Syndax Pharmaceuticals (NASDAQ:SNDX) had its target price boosted by stock analysts at Citigroup from $37.00 to $45.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s price target suggests a potential upside of 182.13% from the company’s previous close.

Several other equities analysts have also recently issued reports on SNDX. StockNews.com upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, November 15th. Stifel Nicolaus raised their price objective on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. The Goldman Sachs Group boosted their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Barclays upped their price target on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a research report on Thursday, August 15th. Finally, UBS Group initiated coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a “buy” rating and a $37.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Syndax Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $37.18.

Syndax Pharmaceuticals Stock Up 1.1 %

Shares of NASDAQ SNDX opened at $15.95 on Tuesday. The business has a 50-day simple moving average of $18.76 and a two-hundred day simple moving average of $20.11. The company has a market cap of $1.36 billion, a P/E ratio of -4.42 and a beta of 0.92. Syndax Pharmaceuticals has a 52 week low of $14.97 and a 52 week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.15. The business had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same quarter last year, the firm earned ($0.73) earnings per share. Equities research analysts anticipate that Syndax Pharmaceuticals will post -3.61 EPS for the current year.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Syndax Pharmaceuticals during the second quarter worth $27,000. Values First Advisors Inc. purchased a new stake in shares of Syndax Pharmaceuticals in the third quarter worth about $30,000. nVerses Capital LLC bought a new stake in Syndax Pharmaceuticals in the second quarter valued at $33,000. Quantbot Technologies LP bought a new position in Syndax Pharmaceuticals in the 3rd quarter worth about $49,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after acquiring an additional 541 shares in the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).